ID: ALA3655086

Max Phase: Preclinical

Molecular Formula: C15H21N5O3S

Molecular Weight: 351.43

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN(c1ncnc2[nH]ccc12)[C@H]1C[C@@H](NS(=O)(=O)CC2COC2)C1

Standard InChI:  InChI=1S/C15H21N5O3S/c1-20(15-13-2-3-16-14(13)17-9-18-15)12-4-11(5-12)19-24(21,22)8-10-6-23-7-10/h2-3,9-12,19H,4-8H2,1H3,(H,16,17,18)/t11-,12+

Standard InChI Key:  DSNWWEIXZLXIAO-TXEJJXNPSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 351.43

Molecular Weight (Monoisotopic): 351.1365

AlogP: 0.49

#Rotatable Bonds: 6

Polar Surface Area: 100.21

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.85

CX Basic pKa: 6.45

CX LogP: -0.21

CX LogD: -0.26

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.79

Np Likeness Score: -0.86

References

1.  (2015)  Pyrrolo[2,3-D]pyrimidine derivatives, 

2. Vazquez ML, Kaila N, Strohbach JW, Trzupek JD, Brown MF, Flanagan ME, Mitton-Fry MJ, Johnson TA, TenBrink RE, Arnold EP, Basak A, Heasley SE, Kwon S, Langille J, Parikh MD, Griffin SH, Casavant JM, Duclos BA, Fenwick AE, Harris TM, Han S, Caspers N, Dowty ME, Yang X, Banker ME, Hegen M, Symanowicz PT, Li L, Wang L, Lin TH, Jussif J, Clark JD, Telliez JB, Robinson RP, Unwalla R..  (2018)  Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.,  61  (3): [PMID:29298069] [10.1021/acs.jmedchem.7b01598]

Source

Source(2):

• Scientific Literature
• BindingDB Database